Stemnovate Platform provides scalable, flexible solution to meet scientific needs for preclinical and clinical R&D.
It integrates different technologies such as cellular reprogramming, cellular differentiation, bioengineering and assay development while providing a compliant framework that supports in vitro R&D and data analysis.
Watch this introductory short video about cell reprogramming
Cellular reprogramming unleashes endless possibilities within drug development and beyond.
Using innovative technology, it’s possible to reprogram adult cells, including skin and blood cells, returning them to a pluripotent state similar to embryonic stem cells.
The resulting induced pluripotent stem cells have the potential to form multiple cell types, including liver, neurons, and bones, thereby generating patient-specific cells.
As well as providing a huge amount of potential for precision medicine, this innovative technique also overcomes the ethical and legal issues associated with the use of embryos.
All cells in the body contain the same genetic information. However, during development, cell fate decisions lead to the attainment of tissue-specific specialisation. But cell fate can be manipulated experimentally. In 2006, Takahashi and Yamanaka identified the transcription regulators that would reprogram adult cells into pluripotency.
Exogenous DNA can be ferried or carried into a cell through viral and non-viral agents. The reprogramming of adult cells is a complex multi-step process, which can include mesenchymal to epithelial transition (MET), activation of endogenous pluripotency machinery, and the genome wide remodelling of chromatin.
Stemnovate provides fully reprogrammed Induced Pluripotent Stem Cells which are:
Compliant: We source cells from consented individuals with accompanying clinical information. Following quality control, primary cells are reprogrammed to pluripotency using non-integrative technology.
Quality: Cell quality control and safety is paramount. We offer PCR based testing solutions for microbial screening.
Pluripotency validation: Cell pluripotency and karyotype stability is examined using state of the art technology.
Cellular differentiation pathways have been defined through the study of embryonic development, gene, and protein expression.
When it’s fertilized, the oocyte forms zygote, which undergoes the first few divisions or cleavage, in order to form cells known as Embryonic Stem Cells. These stem cells have unlimited proliferation, are self-renewing, and have the ability to give rise to all cells in the three germ layers.
At around the third week of embryonic development in humans, the process of gastrulation leads to the cellular transition from pluripotency state to lineage commitment.
Watch this introductory short video about cell differentiation
At this point, the embryo forms an indentation called the primitive streak. Cell migration then occurs, forming the first layer, known as endoderm. Cells such as liver and pancreatic cells are endodermal in origin. The second, middle layer of cells, for example, heart cells and blood cells, is known as mesoderm. The cells that have not migrated through the primitive streak form ectoderm, such as neurons and skin cells.
Our innovative process involves stimulating the development pathway, providing cell growth factors and matrix combinations that result in lineage-specific differentiation. These cells demonstrate functionality that is similar to tissue-specific cells, providing an alternative to primary cells.
Pluripotent stem cell tri-lineage differentiation is examined using standard two and three dimensional differentiation procedures.
Watch this introductory short video about assay development
Drug development and toxicity testing require assays to evaluate the effects of chemical compounds on cellular, molecular or biochemical processes relevant to human health and disease. Stemnovate is the complete solution provider for cellular model development to meet study needs for compound screening, mechanistic studies and preclinical testing.
The miniature organ systems are designed to provide bio-inspired microfluidic environments, in order to allow spatiotemporal control of the various chemical and physical culture conditions that are unavailable with other methods. The three-dimensional cell culture in combination with microfluidics offer significant advantages to model human biology ‘in a dish’ and has potential to ‘fill the gap’ that exists between in vitro and in vivo biology.
Watch this introductory short video about Microphysiological Modelling
Induced Pluripotent stem cells (PSCs) offer unprecedented biomedical potential not only in relation to humans but also companion animals. Several diseases that affect dogs, cats or horses are currently untreatable and can result in euthanasia on medical grounds. In contrast to humans, in vitro models for cellular research for animal studies do not exist.
Our multi-species platform provides a customised approach for species-specific disease modelling to help develop novel treatments for animals where traditional methodologies are inadequate such as complex fractures, spinal cord injuries, cancers, diabetes and much more.